This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / SENTRY Trial Data Myelofibrosis Treatment
Tech medical breakthrough

SENTRY Trial Data Myelofibrosis Treatment

Analysis based on 8 articles · First reported Jun 14, 2026 · Last updated Jun 14, 2026

Sentiment
70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase 3 SENTRY trial results for selinexor plus ruxolitinib in myelofibrosis are expected to positively impact the stock prices of Karyopharm Therapeutics and potentially increase the market value of Menarini Group's subsidiary, AnBogen Therapeutics. This medical breakthrough offers a new treatment option for a rare blood cancer, which could lead to significant revenue generation for the involved pharmaceutical companies.

Pharmaceuticals Biotechnology
Event Summary

Menarini Group and its subsidiary AnBogen Therapeutics, in collaboration with Karyopharm Therapeutics, announced positive data from the pivotal Phase 3 SENTRY trial for selinexor plus ruxolitinib in frontline myelofibrosis. The trial met its primary endpoint, demonstrating a statistically significant improvement in spleen volume reduction (SVR35) at week 24. An encouraging early overall survival signal was also observed, with a greater than 50% reduction in the risk of death for patients receiving the combination. These results, presented at The European Hematology Association 2026 Congress, suggest a potential new therapeutic advance for patients with myelofibrosis, a rare and devastating blood cancer.

Entities Involved
priv
Menarini Group
Menarini Group announced positive Phase 3 SENTRY trial data for selinexor plus ruxolitinib in myelofibrosis, which could lead to a new treatment option and enhance its market position in oncology.
Importance 90.0 Sentiment 75.0
stock
Karyopharm Therapeutics
Karyopharm Therapeutics conducted the SENTRY trial in collaboration with Menarini Group and markets selinexor in the U.S., benefiting from the positive trial data.
Importance 70.0 Sentiment 60.0
ngo
European Hematology Association
The European Hematology Association is hosting the 2026 Congress where the SENTRY trial data will be presented, providing a platform for the announcement.
Importance 20.0 Sentiment 0.0
per
Claire Harrison
Claire Harrison, a professor and deputy chief medical officer, provided an expert opinion on the significance of the SENTRY trial results for myelofibrosis patients.
Importance 10.0 Sentiment 0.0
per
Elcin Barker Ergun
Elcin Barker Ergun, CEO of Menarini Group, expressed optimism about the SENTRY study results and the potential for a new treatment option.
Importance 10.0 Sentiment 0.0
priv
AnBogen Therapeutics
Importance 0 Sentiment 0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.